Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CACNA1B
REST API REST API
Homo sapiens
CACNA1B is differentially expressed in 172 experiments: 124 organism parts: lung, adipose tissue, ... (122 more);, 128 disease states: normal, Huntington's disease, ... (126 more);, 50 cell types 171 cell lines 12 compound treatments and 67 other conditions.
Synonyms CACNL1A5, CACNN, Cav2.2
Orthologs CACNA1B (Bos taurus)   CAC1B_CHICK (Gallus gallus)   F6QCH7_CIOIN (Ciona intestinalis)   Cacna1b (Mus musculus)   cacna1ba (Danio rerio)   Cacna1b (Rattus norvegicus)   cacna1bb (Danio rerio)   LOC100489231 (Xenopus laevis)   CACNA1B (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, transport, protein binding, regulation of heart contraction, ion transport, membrane, locomotory behavior, ion channel activity, voltage-gated calcium channel activity, neurotransmitter secretion, ATP binding, synaptic transmission, dendrite, nucleotide binding, voltage-gated ion channel activity, integral to membrane, protein C-terminus binding, transmembrane transport, calcium ion transport, voltage-gated calcium channel complex, neuronal cell body, membrane depolarization, response to pain, regulation of blood pressure, regulation of calcium ion transport via voltage-gated calcium channel activity, calcium ion transmembrane transport
InterPro Term VDCC_a1su_IQ, PKD_2, VDCCAlpha1, PKD1_2_channel, EF_HAND_2, Ion_trans, VDCC_N_a1su
UniProt Accession Q00975, Q9HAT3, Q9HAT4, Q9HAT5, Q9HAT6, Q9HBI4, Q9HBI3, Q9HBG3, Q9HBG2, Q9HBH2, Q9HBH3, Q9HBH4, B1AQK6, B1AQK4, B1AQK7, Q59FJ3, Q5JRE4, F6RH32, E9PDR3, Q9HBG1
Search EB-eye ENSG00000148408
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-MTAB-24, E-MTAB-25, ... (21 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-22639, E-GEOD-19639, E-GEOD-847, ... (20 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-5823, E-GEOD-19639, E-GEOD-3529
MCF-10A
2
E-TABM-420, E-GEOD-14990
HuPT4
1
E-MTAB-37
MKN45
1
E-GEOD-15460
ib3-1
1
E-MTAB-62
RKO
1
E-MTAB-62
165 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-13909, E-GEOD-13987, E-GEOD-21909, ... (26 experiments)

Factor Value U/D Experiments
human embryonic stem cell
2
E-GEOD-20033, E-GEOD-18265
partially reprogrammed human induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
BDCA4+ dentritic cell
1
E-TABM-145
CD14+ monocyte
3
1
E-AFMX-5
monocyte
1
E-GEOD-995
platelet
1
E-GEOD-2006
44 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-2466, E-GEOD-1869, E-GEOD-2549, ... (39 experiments)

Factor Value U/D Experiments
chronic lymphocytic leukemia
2
E-GEOD-6691, E-GEOD-2466
glioblastoma
2
E-GEOD-4290, E-MTAB-62
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
large cell carcinoma
1
E-MTAB-62
hepatocellular carcinoma, no satellite nodules
1
E-MTAB-62
gastric carcinoma
1
E-GEOD-2685
122 more value(s).


Compound treatment

studied in E-MEXP-1269, E-GEOD-5258, E-GEOD-3284, E-GEOD-412, E-GEOD-2803, ... (10 experiments)

Factor Value U/D Experiments
none
3
E-GEOD-412, E-GEOD-5824, E-GEOD-2803
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
fludrocortisone
1
E-GEOD-5258
unknown
1
E-GEOD-7307
actinomycin D
2
1
E-GEOD-6400
cigarette smoke
2
1
E-TABM-127
6 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
85
1
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-3140, E-GEOD-6236, E-GEOD-4667, ... (6 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-21138, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-MTAB-108, E-MEXP-2340

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-MEXP-421, E-TABM-321, E-GEOD-17347 ... (5 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-TABM-127, E-MEXP-1446, E-GEOD-22278, E-GEOD-9764, ... (6 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-2069, E-GEOD-1926, E-TABM-666, ... (22 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-980

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-1460

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19246, E-GEOD-1343

RNAi
studied in E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

Sex
studied in E-GEOD-2466, E-GEOD-7307

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Treatment
studied in E-GEOD-16837, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290

Tumor size
studied in E-GEOD-6532

Processing time: 0.553 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM